ArticleProtoplasma2026
Tracing the origin of the tobacco BY-2 cell line.
Article in Protoplasma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most frequently used plant cell lines is the tobacco cell line BY-2, which was established from Nicotiana tabacum L. cv. Bright Yellow 2 plants. However, surprisingly, after more than 50 years, the original information about the authors, the place and the method of its establishment is quite laborious to obtain. This could be important for any de novo derivation of highly proliferative cell lines. In this brief reflection article, we summarise the publicly available information on the origin of BY-2 in the 1960s, when it was used in applied research at the Central Research Institute of Japan Tobacco & Salt Public Corporation (JTS). Thanks largely to Professor Toshiyuki Nagata's activities, it spread to the rest of the world in the 1980s, becoming a cellular model for basic research into the cell cycle, membrane and cytoskeletal dynamics, and many other processes. Available literature suggests that the BY-2 cell line was derived from calli induced on the stems of seedlings of the Bright Yellow-2 Virginia-type tobacco cultivar. We hope that the information we have gathered will be useful for everyone working with, or planning to use, the BY-2 cell line. We also hope that it will encourage efforts to search for more details in old Japanese patent records that could be used to establish new, highly proliferating lines.
Indexed as
Identifiers
42399471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.